...
首页> 外文期刊>European Journal of Radiology >Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting.
【24h】

Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting.

机译:低级神经胶质瘤的相对脑血容量测量可在多机构环境中预测患者预后。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/PURPOSE: The prognostic value of defining subcategories of gliomas is still controversial. This study aims to determine the utility of relative cerebral blood volume (rCBV) in predicting clinical response in patients with low-grade glioma at multiple institutions. MATERIALS AND METHODS: Sixty-nine patients were studied with dynamic susceptibility contrast-enhanced perfusion MRI at two institutions. The pathologic diagnoses of the low-grade gliomas were 34 astrocytomas, 20 oligodendroglioma, 9 oligoastrocytomas, 1 ganglioglioma and 5 with indeterminate histology. Wilcoxon tests were used to compare patients in different response categories with respect to baseline rCBV. Kaplan-Meier curve and log-rank tests were used to predict the association of rCBV with time to progression. RESULTS: At both institutions, patients with an adverse event (progressive disease or death) had a significantly higher baseline rCBV than those without (complete response or stable disease) (p value=0.0138). The odds ratio for detecting an adverse event when using rCBV was 1.87 (95% confidence interval: 1.14-3.08). rCBV was significantly negatively associated with time to progression (p=0.005). The median time to progression among subjects with rCBV>1.75 was 365 days, while there was 95% confidence that the median time to progression was at least 889 days among subjects with rCBV<1.75. CONCLUSION: Our study suggests not only that rCBV measurements correlate well with time to progression or death, but also that the findings can be replicated across institutions, which supports the application of rCBV as an adjunct to pathology in predicting glioma biology.
机译:背景/目的:定义神经胶质瘤亚分类的预后价值仍存在争议。这项研究旨在确定相对脑血容量(rCBV)在多个机构中预测低度神经胶质瘤患者临床反应的效用。材料与方法:在两个机构对69例患者进行了动态磁化率对比增强灌注MRI检查。低度神经胶质瘤的病理诊断为34例星形细胞瘤,20例少突胶质细胞瘤,9例少突星形胶质细胞瘤,1例神经节神经胶质瘤和5例组织学不确定的患者。 Wilcoxon测试用于比较基线rCBV不同反应类别的患者。 Kaplan-Meier曲线和对数秩检验用于预测rCBV与进展时间的关联。结果:在这两个机构中,发生不良事件(进行性疾病或死亡)的患者的基线rCBV显着高于未发生不良事件(完全反应或疾病稳定)的患者(p值= 0.0138)。使用rCBV时检测不良事件的比值比是1.87(95%置信区间:1.14-3.08)。 rCBV与进展时间显着负相关(p = 0.005)。 rCBV> 1.75的受试者的中位进展时间为365天,而rCBV <1.75的受试者的中位进展时间至少为889天。结论:我们的研究不仅表明rCBV测量值与疾病进展或死亡时间密切相关,而且该发现可在不同机构间复制,这支持rCBV作为病理学在神经胶质瘤生物学预测中的辅助应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号